Monograph: |
Human insulin soluble
Much of the insulin now produced has an amino-
acid sequence identical to that of human insulin.
Human insulin (emp) is produced by the enzymatic
modification of insulin obtained from the porcine
pancreas; it is also sometimes called semisynthetic
human insulin. The term human insulin (crb) is
used for insulin produced by the chemical combina-
tion of A and B chains which have been obtained
from bacteria genetically modified by recombinant
DNA technology. Human insulin (prb) is produced
from proinsulin obtained from bacteria genetically
modified by recombinant DNA technology. Human
insulin (pyr) is insulin produced from a precursor
obtained from a yeast genetically modified by re-
combinant DNA technology. Human insulin ob-
tained by recombinant DNA technology is
sometimes termed biosynthetic human insulin.
Insulin or human insulin is supplied in a variety of
forms in solution or suspension for injection .
Crystalline insulin may be prepared for
therapeutic use merely by making a solution, either
of acidic or neutral pH. Soluble insulin or 'neutral
insulin' is a short-acting preparation that can be giv-
en intravenously if necessary to cover emergencies.
Soluble formulations are sometimes referred to as
'regular insulin' or 'unmodified insulin': these
names reflect the fact that the preparation has not
been formulated in order to prolong the duration of
action of the insulin.
The action starts within 30 mts to 1 hr , peak effect lasts for about 2-5 hrs and
lasts for 6 to 8 hrs.
|